A Phase 3 interventional study of Empegfilrastim 6 mg and Filgrastim in Chemotherapy-induced Neutropenia, sponsored by Biocad. Completed at 13 sites in Russian Federation. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-24.
Sponsored by Biocad · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing filgrastim in Neutropenia — 1 open to participants now, 1 under way, none of them phase 3. Filgrastim · Neutropenia.
Among the 21 studies testing filgrastim in Neutropenia, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 15th registered.
316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.
Browse Neutropenia studies →1 of the 21 studies testing filgrastim in Neutropenia is open now. Recruiting first, the newest first:
BioGeneric Pharma
Ages 18–55 · Healthy volunteers
Filgrastim: first FDA approval 1991 (NEUPOGEN), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 82 across 230 interventional studies indexed under Neutropenia.
Median enrollment 130 across the 19 interventional studies. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Biocad has 2 studies filed under Neutropenia — fewer than ten, so there is no comparison to draw.
1 of the studies testing filgrastim in Neutropenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07877467BioGeneric PharmaA Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers | 2027-04-07 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing filgrastim in Neutropenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2).
BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated filgrastim empegfilgrastim (Extimia®) at a dose of 6 or 7.5 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients receiving myelosuppressive chemotherapy.
The study also includes the following determination of pharmacokinetic parameters after repeated administration of the study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
Biological: Empegfilrastim 6 mg · Biological: Placebo №2
Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
Biological: Placebo №2 · Biological: Empegfilrastim 7.5 mg
Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
Biological: Filgrastim · Biological: Placebo №1
Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
Also known as: Extimia, metpegfilgrastim, pegylated filgrastim, peg-GCSF
Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
Also known as: GCSF
Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
Also known as: Extimia, metpegfilgrastim, pegylated filgrastim, peg-GCSF
Duration of Neutropenia CTCAE Grade 4
The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).
Time frame: 3 weeks
The Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);
Time frame: 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
The Incidence of Severe Neutropenia (Grade 3-4)
Time frame: 16 weeks
Low Level (Nadir) ANC x 10^9/L
Time frame: 1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
Neutropenia Duration, Any Grade
Time frame: 1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
Duration From ANC Nadir to ANC < 2.0 x 10^9/L
Time frame: 1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
| Milestone | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| Started | 42 | 43 | 43 |
| Completed | 38 | 36 | 36 |
| Not completed | 4 | 7 | 7 |
The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).
| days | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| Duration of Neutropenia CTCAE Grade 4 | 0.905 ± 1.206 | 0.791 ± 1.013 | 1.725 ± 1.519 |
| days | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| 2nd cycle (week 6) | 0.452 ± 1.194 | 0.326 ± 0.919 | 0.925 ± 1.385 |
| 3rd cycle (week 9) | 0.244 ± 0.734 | 0.310 ± 0.680 | 0.641 ± 0.932 |
| 4th cycle (week 12) | 0.195 ± 0.601 | 0.475 ± 1.320 | 0.892 ± 1.197 |
| participants | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| The Incidence of Severe Neutropenia (Grade 3-4) | 40 | 34 | 40 |
| cells x 10^9/L | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| 1st cycle (week 3) | 0.68 ± 0.68 | 0.91 ± 1.11 | 0.47 ± 0.74 |
| 2nd cycle (week 6) | 1.44 ± 1.30 | 2.10 ± 1.78 | 0.87 ± 1.12 |
| 3rd cycle (week 9) | 1.77 ± 1.39 | 1.88 ± 1.71 | 0.94 ± 1.04 |
| 4th cycle (week 12) | 1.67 ± 1.12 | 2.07 ± 1.75 | 0.75 ± 0.87 |
| days | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| 1st cycle (week 3) | 2.214 ± 1.152 | 1.953 ± 1.194 | 4.0 ± 3.121 |
| 2nd cycle (week 6) | 1.881 ± 2.276 | 1.233 ± 1.702 | 2.775 ± 2.434 |
| 3rd cycle (week 9) | 1.585 ± 1.897 | 1.024 ± 1.199 | 2.487 ± 2.480 |
| 4th cycle (week 12) | 1.146 ± 1.195 | 1.525 ± 2.364 | 2.919 ± 2.488 |
| days | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| 1st cycle (week 3) | 1.74 ± 0.98 | 1.51 ± 0.86 | 2.98 ± 2.40 |
| 2nd cycle (week 6) | 1.43 ± 1.29 | 1.05 ± 1.31 | 2.05 ± 1.08 |
| 3rd cycle (week 9) | 1.20 ± 1.21 | 0.98 ± 0.90 | 1.90 ± 1.87 |
| 4th cycle (week 12) | 1.12 ± 1.05 | 1.03 ± 1.20 | 2.14 ± 1.70 |
Collected over 3 month. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empegfilgrastim 6 mg | — | 1/42 (2.4%) | 42/42 (100%) |
| Empegfilgrastim 7.5 mg | — | 1/43 (2.3%) | 43/43 (100%) |
| Filgrastim | — | 5/43 (11.6%) | 43/43 (100%) |
| Event | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| Uterine bleedingReproductive system and breast disorders | 1/42 | 0/43 | 0/43 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/42 | 1/43 | 1/43 |
| Left hand fractureMusculoskeletal and connective tissue disorders | 0/42 | 0/43 | 1/43 |
| nose furunculus 3 gradeInfections and infestations | 0/42 | 0/43 | 1/43 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/42 | 0/43 | 1/43 |
| AgranulocytosisBlood and lymphatic system disorders | 0/42 | 0/43 | 1/43 |
| Event | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim |
|---|---|---|---|
| neutropenia any gradeBlood and lymphatic system disorders | 41/42 | 37/43 | 41/43 |
| LeucopeniaBlood and lymphatic system disorders | 41/42 | 38/43 | 41/43 |
| Weakness / astheniaGeneral disorders | 26/42 | 24/43 | 24/43 |
| AnemiaBlood and lymphatic system disorders | 17/42 | 13/43 | 19/43 |
| HyperglycemiaEndocrine disorders | 6/42 | 8/43 | 9/43 |
| HyperbilirubinemiaHepatobiliary disorders | 7/42 | 7/43 | 2/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/42 | 3/43 | 3/43 |
| Liver enzymes (ALT) elevationHepatobiliary disorders | 4/42 | 2/43 | 2/43 |
| Bone painMusculoskeletal and connective tissue disorders | 4/42 | 4/43 | 2/43 |
| Hyperemia after injectionInjury, poisoning and procedural complications | 3/42 | 0/43 | 0/43 |
| Age, Categorical(Participants) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 42 | 43 | 43 | 128 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| Mean | 48.38 ± 11.07 | 50.42 ± 9.19 | 51.86 ± 9.68 | 50.23 ± 10.03 |
| Sex: Female, Male(Participants) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| Female | 42 | 43 | 43 | 128 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| Russian Federation | 42 | 43 | 43 | 128 |
| Histologic type(participants) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| Infiltrative ductal | 27 | 28 | 33 | 88 |
| Infiltrative lobular | 6 | 3 | 2 | 11 |
| Medullar | 0 | 1 | 0 | 1 |
| Squamous cell cancer | 0 | 1 | 0 | 1 |
| Infiltrative not specified | 4 | 5 | 4 | 13 |
| Low-grade differentiated carcinoma | 2 | 3 | 1 | 6 |
| Undifferentiated cancer | 3 | 2 | 3 | 8 |
| Disease stage(participants) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| IIA | 13 | 12 | 10 | 35 |
| IIB | 5 | 7 | 9 | 21 |
| IIIA | 5 | 7 | 10 | 22 |
| IIIB | 12 | 10 | 8 | 30 |
| IIIС | 2 | 1 | 0 | 3 |
| IV | 5 | 6 | 6 | 17 |
| History previous therapy of breast cancer(participants) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| Adjuvant chemotherapy | 7 | 8 | 10 | 25 |
| Neoadjuvant chemotherapy | 1 | 1 | 0 | 2 |
| Radiotherapy | 8 | 4 | 3 | 15 |
| Hormone therapy | 6 | 7 | 4 | 17 |
| Surgery treatment | 28 | 27 | 22 | 77 |
| Any treatment | 28 | 29 | 26 | 83 |
| Duration of a disease(months) | Empegfilgrastim 6 mg | Empegfilgrastim 7.5 mg | Filgrastim | Total |
|---|---|---|---|---|
| Mean | 16.14 (1.0 to 144.0) | 11.62 (1.0 to 144.0) | 5.37 (1.0 to 51.0) | 11.0 (1.0 to 144.0) |
The record gives a start of Sep 2013, a primary completion of Jun 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Filgrastim